Clinical trialPhase 3Active not recruiting
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
Perioperative Versus Adjuvant FOLFIRINOX for Resectable Pancreatic Cancer: the PREOPANC-3 Study
- Outcome
- Ongoing
- Phase
- Phase 3
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 7 September 2021
- Expected end
- July 2029
- Enrollment
- 378 participants
- Sites
- 21
- Primary outcomes
- Overall survival
- Sponsor
- Other
- Results posted
- No
- Last update
- 15 May 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant mFOLFIRINOX (arm 1) or to upfront surgery followed by 12 cycles of adjuvant mFOLFIRINOX (arm 2). The primary objective of the trial is to determine whether perioperative mFOLFIRINOX improves overall survival compared with adjuvant mFOLFIRINOX in patients with resectable pancreatic cancer.